Indication BioScience LLC is an early-stage drug development company located in Colorado. We are focused on the identification, establishment of intellectual properties, and funding of early stage research on new compounds and formulations for license to larger pharmaceutical manufacturing partners. We have developed and filed patents for a novel approach for the treatment of hypercholesterolemia by reformulating certain existing statin drugs. Indication BioScience LLC first intends to fund supportive research for these hypercholesterolemia drugs, then will seek licensing opportunities. In addition to our hypercholesterolemia drug platform, “Statin+,” we will also establish a drug discovery platform to further the discovery new molecular entities. The new molecules will target the human endocannabinoid receptors, which have been shown as potential targets for treating pain, cancer, neurodegenerative conditions, metabolic disorders, bone growth, and immune system function.
Our company understands the technology and medicine in the health care industry is consistently progressing. Our team of experienced professionals stay current about the latest drug trends.
Our team is working with leading researchers and centers of excellence around the globe, focusing on unlocking the potential of the endocannabinoid system.
Other drug developers will work with us to support clinical trials. We maintain the highest level safety when it comes to testing, manufacturing and transferring of products.
Sign up to receive updates, news, and more.